MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
4.090
-0.020
-0.49%
After Hours: 4.090 0 0.00% 18:12 12/31 EST
OPEN
4.100
PREV CLOSE
4.110
HIGH
4.140
LOW
4.050
VOLUME
14.92M
TURNOVER
--
52 WEEK HIGH
12.36
52 WEEK LOW
3.790
MARKET CAP
2.13B
P/E (TTM)
-2.2605
1D
5D
1M
3M
1Y
5Y
1D
Recursion CFO Ben R. Taylor Reports Sale of Common Shares
Reuters · 12/31/2025 00:35
Takeda, XOMA ink new royalty agreement; amend existing deal
Seeking Alpha · 12/30/2025 13:14
Chief R&D Commercial Officer Najat Khan Sells Recursion Pharmaceuticals Common Shares
Reuters · 12/29/2025 22:25
Weekly Report: what happened at RXRX last week (1222-1226)?
Weekly Report · 12/29/2025 10:07
Is Recursion (RXRX) Finally Proving Its AI Drug Discovery Model With REC-4881’s Early Data?
Simply Wall St · 12/25/2025 13:26
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here?
Barchart · 12/24/2025 08:00
Unusually active option classes on open December 23rd
TipRanks · 12/23/2025 14:40
Cathie Wood's weekly recap: boots bets on AI biotech, crypto; pares back consumer names
Seeking Alpha · 12/22/2025 11:30
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.